AbbVie’s novel epkinly results in meaningful treatment response in patients with treatment-refractory lymphoma
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade ...
Tag: hematology oncology
Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% ...
Venetoclax in addition to ibrutinib effective as a treatment for chronic lymphocytic leukemia
1. High genetic risk participants with chronic lymphocytic leukemia (CLL) taking venetoclax in addition to ibrutinib achieved high rates of ...